Celastrol (NSC 70931)

For research use only.

Catalog No.S1290 Synonyms: Tripterine

8 publications

Celastrol (NSC 70931) Chemical Structure

CAS No. 34157-83-0

Celastrol (NSC 70931, Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

Selleck's Celastrol (NSC 70931) has been cited by 8 publications

2 Customer Reviews

  • SK-BR-3, A549, HCT-116 and BT-474 cells were incubated with or without X66 for 1 h before exposed to GM, celastrol or MG132 for 8 h. Cell lysates were analyzed by Western blot with indicated antibodies.

    Oncotarget, 2016, 7(20):29648-63.. Celastrol (NSC 70931) purchased from Selleck.

    Effects of compound 10 and celastrol on client proteins degradation. Both compound 10 and celastrol induces decreases of Hsp90 client proteins (Akt and Cdk4) through a concentration -dependent manner by Western blot. Meanwhile, compound 10 and celastrol have no effect on the expression level of Hsp90.

    Eur J Med Chem, 2017, 136:63-73. Celastrol (NSC 70931) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Celastrol (NSC 70931, Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.
Features A potent antioxidant and anti-inflammatory drug.
Targets
20S proteasome [1]
(Cell-free assay)
2.5 μM
In vitro

Celastrol at 5 μM inhibits the chymotrypsin-like, PGPH-like, and trypsin-like activities of the purified 20S proteasome by 80%, 5%, and <1%, respectively, whereas at 10 μM, it inhibits these three proteasomal activities by ∼90%, 15%, and <1%, respectively. Celastrol significantly inhibits the proteasomal chymotrypsin activity in PC-3 cells in a concentration-dependent manner. Celastrol at 2.5 μM to 5 μM induces caspase-3 activity by 4.7-fold to 5.5-fold in PC-3 cells. Celastrol (5 μM) treated cells, the levels of the proteasome target proteins, IκB-α and Bax, are increased after 1 hour and further increased to its peak for 4 hours to 12 hours. Celastrol (2.5 μM) treatment induces proteasome inhibition by 40%, as shown by the decreased levels of chymotrypsin-like activity and increased accumulation of ubiquitinated proteins in LNCaP cells. Celastrol (2.5 μM) induces apoptosis in the Celastrol-treated LNCaP cells, as shown by increased levels of caspase-3 activity (up to 3.5-fold), PARP cleavage, and apoptotic morphology. [1] Celastrol (300 nM) is found to suppress LPS-induced production of TNF-alpha and IL-1beta by human monocytes and macrophages. Celastrol (100 nM) also decreases LPS-induced expression of class II MHC molecules by microglia. Celastrol strongly inhibits LPS and IFN-y-induced NO production with IC50 of 200 nM in macrophage lineage cells. Celastrol strongly inhibits TNF-α and IFN-γ-induced NO production with IC50 of 200 nM in endothelial cells. [2] Celastrol (2.5 μM) potentiates the apoptosis induced by TNF and chemotherapeutic agents and inhibits invasion, both regulated by NF-kappaB activation, in KBM-5 cells. Celastrol (2.5 μM) suppresses the expression of TNF induced the expression of gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-XL, c-FLIP, and survivin), proliferation (cyclin D1 and COX-2), invasion (MMP-9), and angiogenesis (VEGF) in KBM-5 cells. Celastrol (5 μM) is found to inhibit the TNF-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 nuclear translocation and phosphorylation, and NF-kappaB-mediated reporter gene expression. [3] Celastrol inhibits proliferating of RPMI 8226, KATOIII, UM-SCC1, U251MG and MDA-MB-231 cells with IC50 of 0.52 μM, 0.54 μM, 0.76 μM, 0.69 μM and 0.67 μM, respectively. Celastrol (1 μM) inhibits growth of RPMI 8226 with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27. Celastrol induces apoptosis in RPMI-8226 cells indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins. Celastrol (1 μM) suppresses Akt pathway and activates JNK kinase in RPMI-8226 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RAW264.7 MoHLRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M2iyVFI1KGi{cx?= MXjBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHnZYlve3RibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBPVyCycn;keYN1cW:wIITy[YF1\WRiMzDodpMh[mWob4LlJGxRWyClaHHscIVv\2ViYYPz[ZN{\WRiYX\0[ZIhOjRiaILzJIJ6KEe{aXXzd{Bz\WGpZX70JIF{e2G7LDDJR|UxKD1iMD6yN{DPxE1w M{K3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzOEC5NFc3Lz5zMUiwPVA4PjxxYU6=
RAW264.7 NVPVWJFnSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NXzmdJJROjRiaILz M3SwcGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIITy[YF1\WRiMzDodpMh[mWob4LlJGxRWyClaHHscIVv\2ViYYPz[ZN{\WRiYX\0[ZIhOjRiaILzJIJ6KFOHQWCgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvOjdizszNMi=> MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6MEmwO|YoRjFzOEC5NFc3RC:jPh?=
RPMI8226 MnXDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M17QcWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHJRVUl6MkK2JINmdGy|LDDJR|UxKD1iMzFOwG0v MnLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNkSxPVcoRjF6MU[0NVk4RC:jPh?=
HeLa NWHxPYRiTnWwY4Tpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIHnuJIh2dWGwIFjlUIEh[2WubIOgZpkhW0WDUDDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4yPSEQvF2u MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG5NFYoRjF6OESxPVA3RC:jPh?=
RAW264.7 NWrvcGNuTnWwY4Tpc44h[XO|YYm= NUDJNo06UW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBPTi2tYYDwZWIh[WO2aY\heIlwdiCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{BjgSCVRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjNizszNMi=> Moj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG5NFYoRjF6OESxPVA3RC:jPh?=
SH-SY5Y NXLZfZd5TnWwY4Tpc44h[XO|YYm= MXnO[ZVzd3C{b4TlZ5Rqd25iYXfhbY5{fCCkZYThMYFugWyxaXSgdIVxfGmmZTCxMVQzNWmwZIXj[YQhfG:6aXPpeJkhcW5iaIXtZY4hW0hvU2m1XUBk\WyuczDhd5Nme3OnZDDhd{Bt[WO2YYTlJIRmcHmmcn;n[Y5ie2VicnXs[YF{\SxiRVO1NEA:KDBwMEO3OlQh|ryPLh?= MmfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzM{i4OVkoRjF7MUO4PFU6RC:jPh?=
HeLa NYTlW5RkTnWwY4Tpc44h[XO|YYm= M1rSe|IhcHK| M2X1emFueGyrZnnjZZRqd25ib3[gTHNHOSC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iaIXtZY4hcGWjdDDzbI9kcy2rbnT1Z4VlKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOg[5JidnWuZTDmc5Ju[XSrb36geJJm[XSnZDCxJIhzKGKnZn;y[UBp\WG2IIPoc4NsKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAzKGi{czD3bZRpd3W2IILlZ493\XK7IITpcYUh[nliaX3teY5w[3m2b3Po[Y1q[2GuIIP0ZYlvcW6pLDDFR|UxKD1iMT6xJO69VS5? NYryc5p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NFIxPTdpPkG5OVAzODV5PD;hQi=>
SK-N-SH M{iwbmN6fG:2b4jpZ4l1gSCjc4PhfS=> M13jcVczKGi{cx?= NVLBXFFLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDDR|UxKD1iMT62JO69VS5? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTVyMkC1O{c,OTl3MEKwOVc9N2F-
HeLa MnPtSpVv[3Srb36gZZN{[Xl? Mn:1N{BpenN? MmPkRY1xdGmoaXPheIlwdiCxZjDIV2YyKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBqdiCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHfyZY52dGViZn;ycYF1cW:wIIDy[ZRz\WG2ZXSg[o9zKDNiaILzJIJ6KGmvbYXuc4N6fG:laHXtbYNidCC|dHHpcolv\yxiRVO1NEA:KDJwNjFOwG0v M37kNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUCyNFU4Lz5zOUWwNlA2PzxxYU6=
HeLa MknZR5l1d3SxeHnjbZR6KGG|c3H5 M2PqUFczKGi{cx?= NImxS3JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEOFNUCgQUA{KM7:TT6= M1K3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUCyNFU4Lz5zOUWwNlA2PzxxYU6=
HeLa MUfGeY5kfGmxbjDhd5NigQ>? Mn7BTY5pcWKrdHnvckBw\iCQRj3rZZBx[UJiYXP0bZZqfHliaX6gbJVu[W5iSHXMZUBk\WyuczDifUBUTUGSIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5zNTFOwG0v NU\Fe3ZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0Olk5QDdpPkKwOFY6QDh5PD;hQi=>
LNCAP NHntdodCdnSrdIXtc5Ih[XO|YYm= NUjwSYZVSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMtKEmFNUCgQUAzNjVizszNMi=> NI\sPVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yO|U2Pid-MkC2Nlc2PTZ:L3G+
PC12 MWLDfZRweHKxdHXjeIl3\SCjc4PhfS=> NUPyb29bS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDD0MWJRUC2rbnT1Z4VlKGOnbHyg[IFu[WenIHnuJJJifCCSQ{GyJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7LDDJR|UxKD1iMz6xOUDPxE1w NFTac2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yO|U2Pid-MkC2Nlc2PTZ:L3G+
PC12 MlTxR5l1d3C{b4TlZ5RqfmViYYPzZZk> NXnsTo5tOS54IIXN NWjKU2RTS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDD0MWJRUC2rbnT1Z4VlKGOnbHyg[IFu[WenIHnuJJJifCCSQ{GyJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFEvPiC3TR?= NGXyco49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yO|U2Pid-MkC2Nlc2PTZ:L3G+
THP1 M1rHfmFxd3C2b4Ppd{Bie3OjeR?= NEfGUYgzPCCqcoO= M3nGPWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gWHJCUUxvcnXzbZN1[W62IHj1cYFvKFSKUEGgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KGGwbnX4bY4uXiC|dHHpcolv\yxiRVO1NEA:KDF3IN88UU4> NGThUJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi2OFM1Oid-MkC4OlQ{PDJ:L3G+
293T Mn\SSpVv[3Srb36gZZN{[Xl? MnXEN|AhdWmwcx?= M3;scWlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUmYuc2GycHHCJIFkfGm4YYTpc44hcW5iaIXtZY4hOjl|VDDj[YxteyCrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhfHKnYYTl[EB4cXSqIFzQV{Bnd3JiNjDodpMh[nliZIXhcE1tfWOrZnXyZZNmKHKncH;yeIVzKGG|c3H5MEBKSzVyIE2gNE4yPyEQvF2u NFPPV2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO5N|AxPCd-MkGzPVMxODR:L3G+
293T NWXvXno2S3m2b4TvfIlkcXS7IHHzd4F6 NVjaTIR[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCkeTDkeYFtNWy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjZ5IN88UU4> M1HFO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{mzNFA1Lz5{MUO5N|AxPDxxYU6=
RAW264 MofkSpVv[3Srb36gZZN{[Xl? M1f5ZVI1KGi{cx?= MmfvTY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDOU{Bxem:mdXP0bY9vKGmwIH3veZNmKFKDV{K2OEBk\WyuczDh[pRmeiB{NDDodpM> NWLqOJdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPVMxODRpPkKxN|k{ODB2PD;hQi=>
NCI-H460 NULFdYZsS3m2b4TvfIlkcXS7IHHzd4F6 MnXUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhd3[ncn7p[4h1KGmwY4XiZZRqd25iYomgUXRVKGG|c3H5MEBKSzVyIE2gNVIvOyEQvF2u MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2Mke2OUc,OjF7NEK3OlU9N2F-
RAW264.7 NGOzOlJCdnSraX7mcIFudWG2b4L5JIF{e2G7 MUiyOEBpenN? MlTPRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIF7PJJBzd2S3Y4Tpc44h[W[2ZYKgNlQhcHK|IHL5JGdzcWW|czDy[YFo\W62IH3leIhw\CxiSVO1NEA:KDFizszNMi=> NWfJcpZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5O|g3PzZpPkKxPVc5Pjd4PD;hQi=>
RAW264.7 NVLkdmE5SW62aXnu[oxidW2jdH;yfUBie3OjeR?= MYCyOEBpenN? M4L0[2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUheHKxZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkh\3KrZYPzJIF{e2G7LDDJR|UxKD1iMTFOwG0v MknLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMkSwN|MoRjJ{MEK0NFM{RC:jPh?=
RAW264.7 NI\FVHVHfW6ldHnvckBie3OjeR?= MnjONVghcHK| MWDJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJG5Hc2GycHHCJIFkfGm4YYTpc44hfHKjboPm[YN1\WRiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[W[2ZYKgNVghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMjFOwG0v NUja[|RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NFUxOjBpPkKyO|A2ODJyPD;hQi=>
spleen adherent cells M2T0[mFvfGmjcoTodol1cWNiYYPzZZk> M1\qdFIxOCC3Zx?= NXLOS4RuSW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBES1J{IHX4dJJme3Orb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cWx? NFOzNpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NGjxOXdCdnSrYYL0bJJqfGmlIHHzd4F6 NEe4THkzODBidXe= NE[yVJZCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGdTVy:NQzDwdo9lfWO2aX;uJIF1KDJyMDD1[{whcXBic4ThdpRqdmdiZoLvcUBienSqcnn0bZMhd26|ZYSgZY5lKGOxboTpcpVm\CC3bnnueIVzenWydHXkJJVvfGl? MoHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUSxPVMoRjJ{OEW0NVk{RC:jPh?=
spleen adherent cells NWHXRpVvSW62aXHyeIhzcXSrYzDhd5NigQ>? NFq0[3EzODBidXe= NV;TRoU5SW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBOS1BzIIDyc4R2[3Srb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cWx? NWfIU|Z6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVQyQTNpPkKyPFU1OTl|PD;hQi=>
spleen adherent cells M2OzXWFvfGmjcoTodol1cWNiYYPzZZk> Ml3UNlAxKHWp MmX0RY51cWG{dHjybZRq[yCnZn\lZ5QhcW5iTHX3bZMhemG2IHHkbpV3[W62LXnu[JVk\WRiYYL0bJJqfGm|IH3v[IVtKHOybHXlckBi\GincnXueEBk\WyuczDy[ZN1cW23bHH0[YQhf2m2aDDzc45q[2G2ZXSgUZRjKHCxc4SgbZNwdGG2aX;uJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDSRW5VTVNicILv[JVkfGmxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRq MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3NEG5N{c,OjJ6NUSxPVM9N2F-
spleen adherent cells MmnnRY51cWG{dHjybZRq[yCjc4PhfS=> MW[yNFAhfWd? M3H4W2FvfGmjcoTodol1cWNiZX\m[YN1KGmwIFzle4l{KHKjdDDh[Ip2fmGwdD3pcoR2[2WmIHHyeIhzcXSrczDtc4RmdCC|cHzl[Y4h[WSqZYLlcpQh[2WubIOgdoV{fGmvdXzheIVlKHerdHigd49vcWOjdHXkJG11[iCyb4P0JIl{d2yjdHnvckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gWG5H[WyyaHGgdJJw\HWldHnvckBifCB{MECgeYctKGmyIIP0ZZJ1cW6pIH\yc40h[XK2aILpeIl{KG:wc3X0JIFv\CClb370bY52\WRidX7pcpRmenK3cITl[EB2dg>? M3zFcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
spleen adherent cells MXrBcpRq[XK2aILpeIlkKGG|c3H5 M3vLbVIxOCC3Zx?= M1XPT2FvfGmjcoTodol1cWNiZX\m[YN1KGmwIFzle4l{KHKjdDDh[Ip2fmGwdD3pcoR2[2WmIHHyeIhzcXSrczDtc4RmdCC|cHzl[Y4h[WSqZYLlcpQh[2WubIOgdoV{fGmvdXzheIVlKHerdHigd49vcWOjdHXkJG11[iCyb4P0JIl{d2yjdHnvckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gR2NTOyCneIDy[ZN{cW:wIHH0JFIxOCC3ZzygbZAhe3SjcoTpcoch\nKxbTDhdpRpemm2aYOgc45{\XRiYX7kJINwdnSrboXl[EB2dmmwdHXydpVxfGWmIIXueIlt NVTifnQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVQyQTNpPkKyPFU1OTl|PD;hQi=>
spleen adherent cells M4XBR2FvfGmjcoTodol1cWNiYYPzZZk> MUmyNFAhfWd? NIfWfIFCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGNEWjZiZYjwdoV{e2mxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRqdA>? NYn5cIxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVQyQTNpPkKyPFU1OTl|PD;hQi=>
spleen adherent cells NHPPTldCdnSrYYL0bJJqfGmlIHHzd4F6 MkXRNlAxKHWp NITiOZRCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGNZS1JzIHX4dJJme3Orb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cWx? NX3Ob4dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVQyQTNpPkKyPFU1OTl|PD;hQi=>
spleen adherent cells Mn35RY51cWG{dHjybZRq[yCjc4PhfS=> MYGyNFAhfWd? NVrsZ|NQSW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBEYEOUMjDlfJBz\XO|aX;uJIF1KDJyMDD1[{whcXBic4ThdpRqdmdiZoLvcUBienSqcnn0bZMhd26|ZYSgZY5lKGOxboTpcpVm\CC3bnnueIVzenWydHXkJJVvfGmu NEK2U5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NIjTXXJCdnSrYYL0bJJqfGmlIHHzd4F6 MXmyNFAhfWd? Mme1RY51cWG{dHjybZRq[yCnZn\lZ5QhcW5iTHX3bZMhemG2IHHkbpV3[W62LXnu[JVk\WRiYYL0bJJqfGm|IH3v[IVtKHOybHXlckBi\GincnXueEBk\WyuczDy[ZN1cW23bHH0[YQhf2m2aDDzc45q[2G2ZXSgUZRjKHCxc4SgbZNwdGG2aX;uJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDDXGNTPCCneIDy[ZN{cW:wIHH0JFIxOCC3ZzygbZAhe3SjcoTpcoch\nKxbTDhdpRpemm2aYOgc45{\XRiYX7kJINwdnSrboXl[EB2dmmwdHXydpVxfGWmIIXueIlt MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUSxPVMoRjJ{OEW0NVk{RC:jPh?=
spleen adherent cells MUfGeY5kfGmxbjDhd5NigQ>? MUmyNFAhfWd? Mn3VTY5kemWjc3WgbY4hS0OUMTDlfJBz\XO|aX;uJIlvKEynd3nzJJJifCCjZHr1eoFvfC2rbnT1Z4VlKGG{dHjybZRqeyCvb3TlcEB{eGynZX6gZYRp\XKnboSgZ4VtdHNicnXzeIlufWyjdHXkJJdqfGhic3;ubYNifGWmIF30ZkBxd3O2IHnzc4xifGmxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRqdCC|dIXkfUBmdmRiYomgdXBEWiC{ZXzheIl3\SCkYYPlcIlv NWPifldZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVQyQTNpPkKyPFU1OTl|PD;hQi=>
spleen adherent cells M2fLR2FvfGmjcoTodol1cWNiYYPzZZk> M3rQPFIxOCC3Zx?= NVr1UGNCSW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBKVC1zYnX0ZUBxem:mdXP0bY9vKGG2IEKwNEB2\yxiaYCgd5RienSrbneg[pJwdSCjcoTodol1cXNib37z[ZQh[W6mIHPvcpRqdnWnZDD1colvfGW{coXweIVlKHWw NEnmN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells MVfBcpRq[XK2aILpeIlkKGG|c3H5 NXrWUm5sOjByIIXn M4rlWWFvfGmjcoTodol1cWNiZX\m[YN1KGmwIFzle4l{KHKjdDDh[Ip2fmGwdD3pcoR2[2WmIHHyeIhzcXSrczDtc4RmdCC|cHzl[Y4h[WSqZYLlcpQh[2WubIOgdoV{fGmvdXzheIVlKHerdHigd49vcWOjdHXkJG11[iCyb4P0JIl{d2yjdHnvckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gR2NTPSCneIDy[ZN{cW:wIHH0JFIxOCC3ZzygbZAhe3SjcoTpcoch\nKxbTDhdpRpemm2aYOgc45{\XRiYX7kJINwdnSrboXl[EB2dmmwdHXydpVxfGWmIIXueIlt M1XwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
spleen adherent cells MoDGSpVv[3Srb36gZZN{[Xl? Mm\0NlQhcHK| NYTJb|ViUW6lcnXhd4UhcW5iQ1PSNUBxem:2ZXnuJJN2em[jY3Wg[ZhxemW|c3nvckBqdiC|b37pZ4F1\WRiTYTiMZN1cW23bHH0[YQhe3CuZXXuJIFlcGW{ZX70JINmdGy|IHnzc4xifGWmIH\yc40hVGW5aYOgdoF1KGGmaoX2ZY51NWmwZIXj[YQh[XK2aILpeIl{KG2xZHXsJJBz\S2rbnP1ZoF1\WRid3n0bEAxNjFidH:gNE4{KHWPIHPvcZBwfW6mIHLl[o9z\SC|dHnteYxifGmxbjD3bZRpKHOxbnnjZZRm\CCPdHKg[o9zKDJ2IHjyd{BjgSCobH;3JIN6fG:v M3W3c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
RAW264.7 Mn;iRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NUPCWoVoOjRiaILz MXzBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvckBi\nSncjCyOEBpenNiYomgS5Jq\XO|IH3leIhw\CxiSVO1NEA:KDFizszNMi=> M2fI[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUK3PFg3Lz5{M{GyO|g5PjxxYU6=
RAW264.7 NUL3N|Q1SW62aXnu[oxidW2jdH;yfUBie3OjeR?= NYmzO3BVOjRiaILz NX;ITFF1SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkig{txONg>? MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{S0NFcoRjJ|MkO0OFA4RC:jPh?=
RAW264.7 MkXTRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M1j1d|I1KGi{cx?= NEP4cnNCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKGenbnXyZZRqd25iaX7jeYJifGWmIH\vdkAzPCCqcoOsJGlEPTBiPTCxJO69VS5? M{fqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO0OFA4Lz5{M{KzOFQxPzxxYU6=
RAW264.7 MVnBcpRqcW6obHHtcYF1d3K7IHHzd4F6 Mn\kRY51cS2rbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUheHKxZIXjeIlwdiCkeTDHdolme3NicnXhZ5Rqd25iYnHz[YQhdWW2aH;kMEBKSzVyIE2gNUDPxE1w NHL3VnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zO|M3Oyd-MkW2N|c{PjN:L3G+
MCF7 NInTdm9EgXSxdH;4bYNqfHliYYPzZZk> NUj4dGtIPzJiaILz MorqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVL2DNV{Bie3OjeTygTWM2OCB;IECuNVU{KM7:TT6= M3Tt[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7 M2PCcGZ2dmO2aX;uJIF{e2G7 MWSyOEBpenN? NWO0VpdvUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJJBCc3RiZHXndoFl[XSrb36gZZQhPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M4HjclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7 MXjGeY5kfGmxbjDhd5NigQ>? MnraNlQhcHK| MkfhTY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IFjldlIh\GWpcnHkZZRqd25iYYSgOUB1cW2nczDJR|UxKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
MCF7 NH;XTXJHfW6ldHnvckBie3OjeR?= MVOyOEBpenN? NFrrVHRKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgR4RsPiCmZXfyZYRifGmxbjDheEA2KHSrbXXzJGlEPTBiYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NU[yPVkoRjJ3N{W2Nlk6RC:jPh?=
MCF7 NX\hZ2pQTnWwY4Tpc44h[XO|YYm= MknENlQhcHK| MX7Jcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiUnHmJIRm\3KjZHH0bY9vKGG2IEWgeIlu\XNiSVO1NEBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NEe5VlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OlI6QSd-MkW3OVYzQTl:L3G+
MCF7 MonXSpVv[3Srb36gZZN{[Xl? M2H1c|I1KGi{cx?= M{f0RWNp[W6pZTDpckBE\GN|NzDlfJBz\XO|aX;uJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiNTD0bY1meyCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NFnSUG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OlI6QSd-MkW3OVYzQTl:L3G+
MCF7 M4rIUmZ2dmO2aX;uJIF{e2G7 M3zG[VI1KGi{cx?= M{SycWNp[W6pZTDpckBxOjNiZYjwdoV{e2mxbjDpckBpfW2jbjDNR2Y4KGOnbHzzJIF1KDVidHnt[ZMhUUN3MDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
MCF7 NXLDfmR6TnWwY4Tpc44h[XO|YYm= M4D3V|I1KGi{cx?= MoTaTY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHTpd5J2eHSrb36gc4YhcW62ZYLhZ5Rqd25id3n0bEBE\GN|NzDheEA2KHSrbXXzJGlEPTBiYX\0[ZIhOjRiaILzJIJ6KGOxLXntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[Xl? NXrUU3VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O|U3Ojl7PD;hQi=>
MCF7 MU\GeY5kfGmxbjDhd5NigQ>? NIG2PYYzPCCqcoO= M2PmbWlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDkbZNzfXC2aX;uJI9nKGmwdHXyZYN1cW:wIIfpeIgheDJ|IHH0JFUhfGmvZYOgTWM2OCCjZoTldkAzPCCqcoOgZpkh[29vaX3teY5weHKnY3nwbZRifGmxbjDhd5NigQ>? NUfURmh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O|U3Ojl7PD;hQi=>
SGC7901 M3;TdmFvfGmlYX7j[ZIh[XO|YYm= NV\pWI5iPDhiaILz NGDwWlRCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gV2dEPzlyMTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF3IN88UU4> NHXZVmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNlk3Pid-MkW4NVI6PjZ:L3G+
SMMC7721 M{fi[mFvfGmlYX7j[ZIh[XO|YYm= NYDLS|k5PDhiaILz NXPMNJF5SW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNOVUN5N{KxJINmdGy|IHHzd4V{e2WmIHHzJINmdGxic4Xyeol3[WxiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwNUig{txONg>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMkm2Okc,OjV6MUK5OlY9N2F-
MGC803 NUWwUFhsSW62aXPhcoNmeiCjc4PhfS=> MkDhOFghcHK| NEPrXppCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWdEQDB|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhe3W{dnn2ZYwh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvPTVizszNMi=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMkm2Okc,OjV6MUK5OlY9N2F-
HepG2 M1y3dWFvfGmlYX7j[ZIh[XO|YYm= MYe0PEBpenN? M2DFNmFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC0MlAyKM7:TT6= NXrNUXd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVI6PjZpPkK1PFEzQTZ4PD;hQi=>
A549 NEnXVVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MW[0PEBpenN? MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIDhZ4xqfGG6ZXytdoV{cXO2YX70JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjBzIN88UU4> M4PDWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkS3N|Y6Lz5{N{[0O|M3QTxxYU6=
A549 NHHEW|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NGTJcpY1QCCqcoO= NUfocoJ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi5yMjFOwG0v NX\HVHZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OFc{PjlpPkK3OlQ4OzZ7PD;hQi=>
MCF7 MnvCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mlf5OFghcHK| NUT6[HYxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi5zMzFOwG0v MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ2N{O2PUc,Ojd4NEezOlk9N2F-
PANC1 MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MoLoOFghcHK| NHTCZ2FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDBUmMyKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi52ODFOwG0v MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ2N{O2PUc,Ojd4NEezOlk9N2F-
LNCAP MmqwSpVv[3Srb36gZZN{[Xl? M3rVNFUhfU1? MWGyOEBpenN? M4DyfmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiQWKgbY4hcHWvYX6gUG5ESVBiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhTEiWLXnu[JVk\WRicnXj[ZB1d3JidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEWgeW0h[W[2ZYKgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 NVSyeWhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzFpPkK3PVk1PzNzPD;hQi=>
A549 Mm\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTo[mRmPiCmYYnz MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzJI1m[XO3cnXkJIV3\XK7IEKgbJJ{KG:4ZYKgOkBl[Xm|IHL5JIxqfmViY3XscEBqdWGpaX7nJIJie2WmIH3leIhw\CxiSVO1NEA:KDBwNkmg{txONg>? NXHEV3U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NlE6PDNpPkK4OlIyQTR|PD;hQi=>
HEK293 NVnzTJNTTnWwY4Tpc44h[XO|YYm= MUSxNEB2VQ>? MlrvNlAhdWmwcx?= M4nVNGlvcGmkaYTpc44hd2ZiR3HsdIhidyCrboTldoFkfGmxbjD3bZRpKEeIUD3meZNm\CCUR2OxO{ApfW6tbn;3ckBwemmpaX6pJIRmdHSjTjDteZRidnRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBTT1NzNzDk[Yx1[U5ibYX0ZY51KGyxY3HsbZpifGmxbjDheEBkgXSxcHzhd40h[XRiMUCgeW0hfXBidH:gNlAhdWmwczDifUBkd26ob3PhcEBucWO{b4Pjc5Bq[yCjbnHsfZNqew>? M3zieFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkKxPVQ{Lz5{OE[yNVk1OzxxYU6=
HEK293 NUW3WItnTnWwY4Tpc44h[XO|YYm= NGnDfWgyODBidV2= MoToOUBucW6| M3TSU2lvcGmkaYTpc44hd2ZiR3HsdIhiOCCrboTldoFkfGmxbjD3bZRpKEeIUD3meZNm\CCUR2OxO{ApfW6tbn;3ckBwemmpaX6pJIRmdHSjTjDteZRidnRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBTT1NzNzDk[Yx1[U5ibYX0ZY51KGyxY3HsbZpifGmxbjDheEBkgXSxcHzhd40h[XRiMUCwJJVOKHWyIITvJFUhdWmwczDifUBkd26ob3PhcEBucWO{b4Pjc5Bq[yCjbnHsfZNqew>? NYCwVlZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NlE6PDNpPkK4OlIyQTR|PD;hQi=>
HEK293 NVfPdIxyTnWwY4Tpc44h[XO|YYm= NGjEV20yOCC3TR?= MUm1JI1qdnN? NXfvV|NPUW6qaXLpeIlwdiCxZjDHZYxxcGGxIHnueIVz[WO2aX;uJJdqfGhiR1\QMYZ2e2WmIGLHV|E4KCi3bnvuc5dvKG:{aXfpckkh\GWudHHOJI12fGGwdDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFKJU{G3JIRmdHSjTjDteZRidnRibH;jZYxqgmG2aX;uJIF1KGO7dH;wcIF{dSCjdDCxNEB2VSC3cDD0c{A2KG2rboOgZpkh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXN? NWHhTGNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NlE6PDNpPkK4OlIyQTR|PD;hQi=>
MIAPaCa2 MojxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXHuUo9GPzJiaILz MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlQ3KM7:TT6= NHnOcIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
SKBR3 NILpS2hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3PRWVczKGi{cx?= MnjxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS1LSN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD63NkDPxE1w NHy2b5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
SKOV3 MknHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFj6UWY4OiCqcoO= MlXjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS1;WN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMT6xOkDPxE1w MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEiyPFEoRjJ6Nki4NlgyRC:jPh?=
MDA-MB-231 M3j5UGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{S3bFczKGi{cx?= NYXCU4pkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkOyJO69VS5? NH63cWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
A549 NWiwUXFWSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX23NkBpenN? NUPiPYdiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlU3KM7:TT6= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OEK4NUc,Ojh4OEiyPFE9N2F-
BJ MUDDfZRwfG:6aXPpeJkh[XO|YYm= M4PqPVczKGi{cx?= MkTVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjd2IN88UU4> NGr0c2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
NCI-H460 NEPzSZdHfW6ldHnvckBie3OjeR?= NE\5ZZoyKHWP MlTFNVIhcHK| NIDqdGlC[3SrdnH0bY9vKG:oIFjTSlEhcW5iaIXtZY4hVkOLLVi0OlAh[2WubIOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJGhUWDJ3IIDyc5RmcW5ibHX2[Yx{KGG2IEGgeW0h[W[2ZYKgNVIhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NH3PXHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezO|kyPid-Mki3N|c6OTZ:L3G+
NCI-H460 MmjLSpVv[3Srb36gZZN{[Xl? MWKxJJVO NVn2eItJOTJiaILz NYPSNolDSWO2aY\heIlwdiCxZjDIV2YyKGmwIHj1cYFvKE6FST3IOFYxKGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBJW1B5MDDwdo91\WmwIHzleoVteyCjdDCxJJVOKGGodHXyJFEzKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NHnFNGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezO|kyPid-Mki3N|c6OTZ:L3G+
NCI-H1299 NHPvboxEgXSxdH;4bYNqfHliYYPzZZk> NFfsXVlEgXSxdH;4bYNqfHliaX6gbJVu[W5iTlPJMWgyOjl7IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTygTWM2OCB;IEGg{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3NES3NEc,Ojh5NUS0O|A9N2F-
BCP-ALL M3\QTmN6fG:2b4jpZ4l1gSCjc4PhfS=> M2D4eGN6fG:2b4jpZ4l1gSCrbjDoeY1idiCEQ2CtRWxNKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NEA:KDFizszNMi=> M3TPVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W0OFcxLz5{OEe1OFQ4ODxxYU6=
T-ALL NG\p[I5EgXSxdH;4bYNqfHliYYPzZZk> MlnXR5l1d3SxeHnjbZR6KGmwIHj1cYFvKFRvQVzMJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUwhUUN3MDC9JFEh|ryPLh?= Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NUS0O|AoRjJ6N{W0OFcxRC:jPh?=
Daudi MVLDfZRwfG:6aXPpeJkh[XO|YYm= NE\rNVNEgXSxdH;4bYNqfHliaX6gbJVu[W5iRHH1[Ikh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6NCCLQ{WwJF0hOSEQvF2u M4jRe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W0OFcxLz5{OEe1OFQ4ODxxYU6=
HL60 M2ToSWN6fG:2b4jpZ4l1gSCjc4PhfS=> MnrsR5l1d3SxeHnjbZR6KGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyIE2gNUDPxE1w M{jE[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W0OFcxLz5{OEe1OFQ4ODxxYU6=
TC32 M2PyU5FJXFNiYYPzZZk> MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MlLKdWhVWyCjc4PhfS=> MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NH\wfos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 MmP4dWhVWyCjc4PhfS=> M{DxRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 MVLxTHRUKGG|c3H5 NV\xb5k5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NH3TeHByUFSVIHHzd4F6 NH;H[YdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NInqWGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 Mon6dWhVWyCjc4PhfS=> MmX0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NHWzTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M3LF[pFJXFNiYYPzZZk> NILkXlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> NHXiPVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MXrxTHRUKGG|c3H5 NXzWWlk5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NV\ZdGJteUiWUzDhd5NigQ>? MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M1vEW5FJXFNiYYPzZZk> MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 Mmf1dWhVWyCjc4PhfS=> NXPWWIpseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NIrLUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 MkXOdWhVWyCjc4PhfS=> MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 M2PqZZFJXFNiYYPzZZk> NXrEOmVSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= MnTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NUm5SZloeUiWUzDhd5NigQ>? MkjodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NXHxcZpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NVr1dVNweUiWUzDhd5NigQ>? MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) M2fiZ5FJXFNiYYPzZZk> MnW4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NVn3Upk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 MnvDdWhVWyCjc4PhfS=> M2nlb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy| NFr2N2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MoHQdWhVWyCjc4PhfS=> NYDLUHl2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= MorTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NHO0e|RyUFSVIHHzd4F6 NFXHdVVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN? MkfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MoXsdWhVWyCjc4PhfS=> NEf4T5pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NWmydFE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MnrJdWhVWyCjc4PhfS=> NGflcI9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NYPD[ZYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NV76NZZVeUiWUzDhd5NigQ>? MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> NGrtcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 Mm\PdWhVWyCjc4PhfS=> MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=> M4jtV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M3jKTJFJXFNiYYPzZZk> NYDJfmQ3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NGTRNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M3j0b5FJXFNiYYPzZZk> NIjyfJlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy| NGXjdJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NYnvSpRveUiWUzDhd5NigQ>? MlrMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>? NXrDPIJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MXjxTHRUKGG|c3H5 M3:yRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{ MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MUDxTHRUKGG|c3H5 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR|MzKGOnbHzz M2rK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NHrpUmFyUFSVIHHzd4F6 NVTmR5d4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NUfZXGpvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells NXjKVY1peUiWUzDhd5NigQ>? NVfJZmU{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG|dDDj[Yxtew>? M17SUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MkXtdWhVWyCjc4PhfS=> MnLsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{ M4rJVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 MWLxTHRUKGG|c3H5 NIjQRnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ NVXjSoJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NFK4TVlyUFSVIHHzd4F6 MkO4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NE[2Z|dyUFSVIHHzd4F6 MkLYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> MojRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 MU\xTHRUKGG|c3H5 NVuydYc4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NIXQfXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NETnbZZyUFSVIHHzd4F6 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM> NYfJXVFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MVnxTHRUKGG|c3H5 MnTEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{ NVz3UVJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NWS1eG1beUiWUzDhd5NigQ>? M4LofZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
HCT116 MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGDMU2Q1QCCqcoO= Mmn6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuNlYh|ryPLh?= M174c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU1Lz5{OUS4Olk2PDxxYU6=
HepG2 NYnvV5RHSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX60PEBpenN? MoqyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iNj6xO{DPxE1w M4HXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU1Lz5{OUS4Olk2PDxxYU6=
A549 MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGfnR4E1QCCqcoO= MmHIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB4LkW5JO69VS5? NH[xPVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2PCd-Mkm0PFY6PTR:L3G+
MCF7 M2T4eGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M37mflQ5KGi{cx?= NX7vZW15SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC2Mlg1KM7:TT6= NW[2dGtbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTRpPkK5OFg3QTV2PD;hQi=>
HEK293 NVjLRm45S3m2b4TvfIlkcXS7IHHzd4F6 NWjWbGRRS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJEhEVy2DRFS6UWFgODB5KUugR2M2OCCkeTDj[YxtKH[rYXLpcIl1gSCjc4PhfUBqdiCGTVXNJEgyOCViRlLTLUBu\WSrYTD1d4lv\yCWQzDwcIF1\XNuIHL5JHJme2G8dYLpckBHMDV4MD:1PVAqNCCFQ{WwJF0hOC56M{eg{txONg>? M3\XflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOTl6Mj:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HIF-1α; 

PubMed: 25383959     


Celastrol enhanced HIF-1α expression in multiple cell lines. MCF-7, HeLa, PC-3 and H1299 cells were treated with the indicated doses of Celastrol for 12 h under 3% hypoxia, and western blotting was used to detect the HIF-1 proteins.

Akt / p-Akt / p-p70S6K ; 

PubMed: 25383959     


Celastrol induced AKT/p70S6K activation under normoxia and hypoxia. HepG2 cells were challenged with the indicated doses of Celastrol for 6 h under normoxia or hypoxia. The protein levels were analyzed by western blotting with the corresponding antibodies. 

PARP / p53 / p21 / cIAP1 / Bcl-xl / Bcl-2 ; 

PubMed: 25383959     


Celastrol transiently activates p53 under normoxia but persistently activates p53 under hypoxia. HepG2 cells were cultured in normoxia or hypoxia with or without 4 µM Celastrol for the indicated times. The proteins were detected by western blotting. 

IκBα / p-IKKα/β ; 

PubMed: 28388439     


Inhibition of TNFα-induced IKKα/β phosphorylation and IκBα degradation by celastrol. Cells treated with celastrol and/or TNFα (20 ng/mL) for 30 min were analyzed by western blotting (WB).

iNOS / COX-2 / Arg-1 ; 

PubMed: 29040966     


Effects of celastrol on the expression of iNOS, COX‐2 and arginase-1 in LPS-stimulated RAW264.7 cells. After 24 h treatment with LPS and/or celastrol, the cellular proteins were analyzed by Western blotting with specific antibodies and GAPDH (as loading control). The blots (n = 3) were quantified by a densitometric method. Representative blots were shown

Chk2 / p-Chk2 / Cyclin B1 / Cdc25c / p-Cdc25c ; 

PubMed: 31053160     


U251, U87-MG and C6 cells were treated with celastrol (0, 0.3, 1, 3 and 10 μM) for 24 h. The levels of cell cycle-associated protein expressions were analyzed by western blotting. β-actin was used as an internal control.

25383959 28388439 29040966 31053160
Immunofluorescence
p21 / Nur77 ; 

PubMed: 28388439     


Colocalization of Nur77 with p62. Representative images illustrate colocalization of transfected endogenous Nur77 (E) or transfected GFP-Nur77 (F) with p62 in HepG2 cells after treatment with 4 μM celastrol and 20 ng/mL TNFα for 1 hr, analyzed by immunostaining. Scale bar, 10 μm.

28388439
Growth inhibition assay
Cell viability; 

PubMed: 29040966     


Cytotoxicity of celastrol. Following 48 h treatment, RAW264.7 cells were determined for the cell viability by a colorimetric MTT assay relative to the untreated controls (n = 3). **, p < 0.01 (Celastrol vs Control).

29040966
In vivo Celastrol (3 mg/kg) results in significant inhibition (up to 70%) of tumor growth in male nude mice bearing PC-3 tumors, associated with increased p27 levels and Bax level. Celastrol (3 mg/kg) results more apoptotic tumor cells with the appearance of various PARP cleavage fragments in tumor of male nude mice bearing PC-3 tumors. Celastrol (3 mg/kg) causes 35% of tumor inhibition, associated with decreased proteasome activity and decreased expression of AR protein in nude mice bearing C4-2B tumors. [1] Celastrol (3 mg/kg) is found to suppress strongly joint swelling and other manifestations of adjuvant arthritis in mice. Celastrol (0.2 mg/kg) significantly improves the performance in memory, learning and psychomotor activity tests in rats. [2]

Protocol

Kinase Assay:[1]
- Collapse

Inhibition of purified 20S proteasome activity:

A purified rabbit 20S proteasome (0.1 μg) is incubated with 40 μM of various fluorogenic peptide substrates in 100 μL assay buffer (20 mM Tris-HCl (pH 7.5)), in the presence of Celastrol at different concentrations or in the solvent DMSO for 2 hours at 37 ℃, followed by measurement of inhibition of each proteasomal activity.
Cell Research:[4]
- Collapse
  • Cell lines: RPMI 8226, KATOIII, UM-SCC1, U251MG and MDA-MB-231 cells
  • Concentrations: ~5 μM
  • Incubation Time: 2 hours
  • Method: The anti-proliferative effect of celastrol on various human tumor cell lines is determined by the MTT uptake method. Briefly, 5×103 cells are incubated with Celastrol in triplicate in a 96-well plate at 37 ℃. MTT solution is then added to each well. After a 2 hours incubation at 37 ℃, extraction buffer (20% SDS, 50% dimethylformamide) is added, cells are incubated overnight at 37 ℃, and the optical density is then measured at 570 nm using a Tecan plate reader.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: nude mice bearing C4-2B tumors
  • Dosages: 3 mg/kg
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (199.72 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.61
Formula

C29H38O4

CAS No. 34157-83-0
Storage powder
in solvent
Synonyms Tripterine
Smiles CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Related Proteasome Products

Tags: buy Celastrol (NSC 70931) | Celastrol (NSC 70931) supplier | purchase Celastrol (NSC 70931) | Celastrol (NSC 70931) cost | Celastrol (NSC 70931) manufacturer | order Celastrol (NSC 70931) | Celastrol (NSC 70931) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID